# Yunnan Baiyao: Uses, Evidence, and Veterinary Safety Yunnan Baiyao is a proprietary Chinese herbal medicine, sold as a dietary supplement rather than an FDA-approved drug, that veterinarians and pet owners use most often to try to reduce bleeding in dogs with hemangiosarcoma, persistent nosebleeds, or bleeding around surgery. Its exact formula is a trade secret. The published veterinary evidence is thin: a handful of small canine and feline studies, a few case reports, and rodent models, with no large randomized canine or feline trials showing that it stops bleeding or prolongs survival. This article reviews what is known about its composition, its claimed uses, the quality of the evidence behind each claim, and the safety and regulatory issues a veterinarian or pet owner should weigh before using it. This article is educational and is not a substitute for veterinary diagnosis or treatment. ## At a Glance | Feature | Detail | |--|--| | Product type | Proprietary Chinese herbal blend sold as a dietary supplement | | Key disclosed component | Panax notoginseng (notoginseng root) | | Other known constituents | Aconitum kusnezoffii (Cao-wu, caowu) among the undisclosed ingredients [1] | | Common veterinary forms | 250 mg capsules and 16 mg topical powder (per product labeling) | | Species commonly given | Dogs, and less often cats | | Typical label use | Control of bleeding, wound healing, bruising, pain | | How it is given | Orally as capsules or powder, or applied topically to wounds | | Onset and duration | Not established by controlled veterinary data | | Regulatory status | Not FDA-approved as a drug. Marketed as a supplement | | Prescription needed | No. Sold over the counter and online | ## What Yunnan Baiyao Is Yunnan Baiyao is one of the best known traditional Chinese medicine formulas. It has been used in human medicine in China for roughly a century as a hemostatic, meaning a substance intended to stop bleeding, and it is also promoted for wound healing, bruising, swelling, and pain [2][1]. In veterinary practice it is most often reached for when a clinician wants to try to slow bleeding that is not easily controlled by surgery or by conventional drugs, particularly in dogs with bleeding tumors. The formula is proprietary. The manufacturer does not disclose the full list of ingredients or their proportions, which is a central problem for anyone trying to reason about its pharmacology or its toxicology. What is publicly known is that Panax notoginseng, the root of a plant in the ginseng family, is a key component, and that Aconitum kusnezoffii, known in Chinese medicine as Cao-wu or caowu, is also present [1]. Caowu is a plant that contains aconite-type alkaloids, which are the same class of compounds responsible for the toxicity of monkshood. That single fact drives much of the safety discussion later in this article. Because the full formula is not published, no one outside the manufacturer can state with confidence which compounds are responsible for any observed effect, how much of each is present in a capsule, or how a batch from one production run compares with the next. Reviews of the pharmacology of Yunnan Baiyao note that identifying the active ingredients remains an open research question [2]. ## Claimed Uses in Veterinary Medicine ### Epistaxis and Other Surface Bleeding Epistaxis means bleeding from the nose. It is one of the most common reasons a dog is given Yunnan Baiyao, particularly when the bleeding is chronic and no obvious cause is found. The rationale is straightforward: if the product promotes clotting, it might reduce the volume or duration of bleeding from fragile nasal vessels. The evidence for this specific use in dogs and cats is limited to clinical experience and case reports rather than controlled trials. In one report of two dogs with idiopathic renal hematuria, meaning blood in the urine from the kidney with no identified cause, treatment with Yunnan Baiyao was unsuccessful and both dogs ultimately required a different procedure to stop the bleeding [3]. That is a single negative observation, not proof that the drug never works for surface bleeding, but it is a reminder that clinical improvement attributed to the product can be coincidence or natural resolution. ### Hemangiosarcoma-Associated Bleeding Hemangiosarcoma is a cancer of blood vessel lining cells. It most often arises in the spleen or the heart, and it is notorious for causing sudden, severe internal bleeding when a tumor ruptures. Yunnan Baiyao is widely used in these dogs, both to try to reduce bleeding and in the hope that it might slow the cancer itself. The most direct laboratory evidence comes from a study that exposed three canine hemangiosarcoma cell lines to increasing concentrations of Yunnan Baiyao in the laboratory. The product caused dose-dependent and time-dependent cell death through caspase-mediated apoptosis, a programmed form of cell suicide, with half-maximal inhibitory concentrations at 72 hours of roughly 276 to 370 micrograms per milliliter depending on the cell line [4]. That finding supports further study, but it does not show that the drug reaches such concentrations in a living dog or that it shrinks tumors in patients. Clinical evidence is weaker. A retrospective study of 104 dogs with hemangiosarcoma found that dogs recorded as receiving Yunnan Baiyao had a longer disease-free interval, while dogs that received blood transfusions had a shorter one [5]. Retrospective studies of this kind cannot establish cause and effect, because the decision to give the drug was made by clinicians who may have selected patients with better prognoses. A single case report described a dog with splenic and intraocular hemangiosarcoma that survived two years on a regimen combining metronomic chemotherapy with Yunnan Baiyao and a polysaccharopeptide supplement [6]. Case reports describe what happened in one patient. They cannot show that the drug was responsible. ### Surgery and Procedural Bleeding The idea that Yunnan Baiyao reduces surgical blood loss comes mainly from human oral and maxillofacial surgery. A randomized, double-blind, placebo-controlled trial in patients undergoing bimaxillary orthognathic surgery found that preoperative Yunnan Baiyao capsules reduced mean intraoperative blood loss compared with placebo [7]. That result applies to people, not dogs, and it cannot be transferred directly to veterinary patients. In dogs, the relevant studies have looked at laboratory measures of clotting rather than actual surgical blood loss, and those results have been mixed, as described in the next section. ### Wound Healing and Topical Use Yunnan Baiyao powder has a long history of topical use on cuts and abrasions in people, and it is sometimes applied to wounds in animals. A 2023 study built a microneedle patch that loaded Yunnan Baiyao into a polysaccharide base and tested it in rats. The patch promoted platelet adhesion and activated the coagulation system in a rat liver hemorrhage model, and it accelerated wound healing in rat skin wounds by increasing new blood vessel formation, fibroblast density, and collagen deposition [8]. This is an engineered device tested in rodents. It tells us something about the biological activity of the herb, but it does not tell us that sprinkling the powder on a dog's wound will speed healing. An older veterinary study examined Yunnan Baiyao as a material for repairing perforations in the floor of the pulp chamber in dog teeth. The Yunnan Baiyao group had milder early inflammation than the other materials tested, and later stages showed cementum formation and new alveolar bone around the repair site [9]. This is a narrow dental application from 1994 and is not a basis for general wound care recommendations. ### Anti-inflammatory and Other Claims Laboratory work has explored anti-inflammatory effects. One study found that Yunnan Baiyao reduced pro-inflammatory cytokines and the expression of cyclooxygenase-1, cyclooxygenase-2, 5-lipoxygenase, and prostaglandin E2 in osteoclasts stimulated with lipopolysaccharide [10]. Another review summarized proposed mechanisms including platelet activation, regulation of arachidonic acid metabolism, and autophagy regulation, and cited human clinical effects such as reduced bleeding in orthognathic surgery and faster healing of diabetic ulcers [2]. These are mechanistic and human findings. They are interesting for understanding how the formula might work, but they are not veterinary efficacy data. ## Claimed Use Versus Evidence Level Versus Species Studied | Claimed use | Evidence level | Species studied | |--|--|--| | Reduces bleeding in hemangiosarcoma | Very low. In vitro cell death plus one retrospective association [4][5] | Dogs (laboratory and retrospective records) | | Reduces epistaxis or surface bleeding | Very low. Case reports only, including treatment failures [3] | Dogs | | Reduces surgical blood loss | Low in humans, absent in dogs. One human randomized trial [7] | Humans | | Improves clotting on laboratory tests | Conflicting. One study found increased clot strength, two found no clinically significant change [11][12][13] | Dogs | | Improves clotting in cats | Very low. No significant change in clotting parameters, with vomiting reported [14] | Cats | | Improves clotting in horses | Very low. No effect on any hemostatic variable [15] | Horses | | Speeds wound healing | Low. Rodent model with an engineered patch [8] | Rats | | Reduces inflammation | Low. Laboratory cell studies [10] | Cultured cells | | Repairs dental perforations | Very low. Single older study [9] | Dogs | | Prolongs survival in hemangiosarcoma | Very low. One retrospective association and one case report [5][6] | Dogs | ## How It Is Thought to Work The proposed mechanisms fall into several categories. The first is platelet activation. Platelets are the cell fragments in blood that clump together to form the initial plug at a site of injury. Laboratory work suggests that components of Yunnan Baiyao can promote platelet adhesion and activation, which would in theory speed the formation of a clot [8][2]. The second is effects on arachidonic acid metabolism, the biochemical pathway that produces prostaglandins and related signaling molecules involved in inflammation and in the regulation of blood flow [2][10]. The third is direct cytotoxicity against cancer cells, demonstrated in hemangiosarcoma cell lines through caspase-mediated apoptosis [4]. The fourth is a general anti-inflammatory effect, shown in cultured osteoclasts through reduced cytokine production [10]. None of these mechanisms has been confirmed to operate at clinically meaningful levels in a living dog or cat receiving oral Yunnan Baiyao. The gap between a laboratory finding and a clinical effect is where most of the uncertainty in this field sits. ## What the Controlled Veterinary Studies Actually Show This is the part of the story that is most often skipped. Several groups have given Yunnan Baiyao to healthy animals and measured clotting with thromboelastography, a test that tracks the physical properties of a forming clot, and with other coagulation assays. The results do not agree with each other, and none of them shows a clear, clinically important effect. In one randomized controlled crossover trial, eight beagle dogs received either placebo or 1000 mg of Yunnan Baiyao orally every 12 hours for five treatments. Buccal mucosal bleeding time, a measure of how long a small standardized cut in the mouth takes to stop bleeding, and thromboelastography parameters were measured. There were no adverse effects and no significant differences between the treated and control dogs at any time point [11]. A second study from a related group used the same dosing schedule and measured thromboelastography plus prothrombin time, activated partial thromboplastin time, fibrinogen, and D-dimers. Oral Yunnan Baiyao increased the R-time, which reflects the time to the start of clot formation, significantly within the treated group, but the value stayed within the normal canine reference range. No other changes were seen, and the authors concluded that the product did not produce a significant improvement in hemostatic parameters at that dose and frequency [13]. A third study took a different approach. Eighteen client-owned dogs weighing at least 15 kg received one 250 mg capsule of Yunnan Baiyao orally twice daily for one week. This time, treated dogs had significantly increased G, A30, and A60 values, which indicate a stronger clot, and significantly decreased LY30 and LY60 values, which indicate less clot breakdown. Only one dog developed mild diarrhea [12]. This is the one canine study that found a procoagulant signal, and it used a lower dose than the beagle studies. The authors called their findings preliminary and asked for larger prospective studies in different disease states. In cats, twenty client-owned cats were enrolled and seventeen began treatment with one 250 mg capsule twice daily for a week. One cat could not finish because of severe vomiting attributed to the product, and two more had transient vomiting. Yunnan Baiyao administration was associated with a significant decrease in hematocrit and [red blood cell](/blog/guides/red-blood-cell) count, though no cat became anemic, and none of the thromboelastography parameters changed significantly [14]. In horses, twelve healthy adults received Yunnan Baiyao paste at 15 mg/kg orally every 12 hours for three days in a randomized blinded crossover design with a four-week washout. The researchers measured platelet activation, coagulation, fibrinolysis, von Willebrand factor, and thromboelastography. Yunnan Baiyao had no significant effect on any hemostatic variable compared with placebo [15]. Taken together, these studies show that oral Yunnan Baiyao does not reliably change standard clotting tests in healthy animals. The one positive canine finding used a different dose and a different population, and it has not been replicated. A systematic review and meta-analysis of human randomized trials found statistical signals in favor of Yunnan Baiyao for hemorrhage and ulcer treatment, but it also found substantial heterogeneity and evidence of publication bias, and the treatment effect became unstable when trials at high risk of bias were removed [16]. That pattern, a positive pooled result that weakens when weak studies are excluded, is a caution sign rather than a green light. ## How It Is Given Yunnan Baiyao is most commonly given by mouth. The commercial capsules are typically labeled at 250 mg each, and the topical powder at 16 mg per dose, according to the product labeling. The published veterinary studies used one 250 mg capsule twice daily in dogs and cats [12][14] and 1000 mg every 12 hours in beagles [11][13]. These are research protocols, not established clinical doses, and they produced inconsistent results. There is no universally accepted veterinary dose. The product can also be applied topically to wounds as a powder. In human practice, the capsule contents are sometimes emptied onto a wound or taken with water. In animals, the most common route is oral, either as a capsule hidden in food or as powder mixed with a small amount of palatable food. Because the formula is proprietary, the amount of any individual constituent in a given capsule is not known to the prescriber. That makes precise dosing impossible in the usual pharmacological sense. If a veterinarian chooses to use the product, the sensible approach is to follow the label, record the exact product and batch, and avoid combining it with other drugs that affect clotting without a clear reason. ## Side Effects and What to Do About Them The most commonly reported side effect in the veterinary studies was gastrointestinal upset. In the canine study that found a procoagulant effect, one dog developed mild diarrhea [12]. In cats, vomiting was more prominent: one cat was withdrawn from the study because of severe vomiting, and two others had transient vomiting [14]. Cats appear to tolerate the product less well than dogs in the available data. The feline study also found a significant decrease in hematocrit and red blood cell count, although no cat became anemic [14]. The clinical importance of this finding is uncertain, but it is a reason to check a complete blood count if a cat is given the product for more than a short course. The more serious safety concern is the presence of Aconitum kusnezoffii, or caowu, in the formula. Aconite alkaloids are cardiotoxic and neurotoxic, and they are the main source of Yunnan Baiyao's recognized toxicology [1]. Research using [network pharmacology](/knowledge/bioinformatics/network-pharmacology-approaches-to-multi-target-drug-discovery) and metabolomics in rats has examined how the other components of the formula may attenuate the toxicity of caowu, which implies that the raw ingredient is toxic enough that detoxification matters [17]. The developmental no-observed-adverse-effect level for embryos and fetuses in rats has been reported at 0.5 g/kg [1]. These are rodent data. They do not define a safe dose in dogs or cats, but they establish that the formula contains a genuinely toxic plant constituent and that dose matters. If a pet vomits, develops diarrhea, becomes lethargic, loses appetite, or shows any neurological or cardiac signs after receiving Yunnan Baiyao, stop the product and contact a veterinarian. Because the formula is undisclosed, there is no specific antidote, and treatment is supportive. ## Which Animals Should Not Receive It There is no formally established list of contraindications for veterinary patients, because the product has never been through the drug approval process that generates such labeling. Reasonable caution applies in several situations. Animals with known liver or kidney disease may clear any toxic constituents more slowly. Pregnant or breeding animals should not receive it, given the reproductive toxicology signal in rats and the aconite content [1]. Cats deserve particular caution because of the vomiting and red blood cell changes seen in the feline study [14]. Animals with a known bleeding disorder, or those already on anticoagulants or antiplatelet drugs, should not receive it without direct veterinary supervision, because combining a product with uncertain procoagulant activity and a drug that thins the blood is unpredictable. Animals scheduled for surgery present a specific problem. Some clinicians give Yunnan Baiyao before surgery hoping to reduce bleeding, but there is no canine evidence that it reduces surgical blood loss, and the product's effect on clotting tests in dogs is inconsistent [11][12][13]. The decision should be made by the attending veterinarian with knowledge of the individual patient. ## Interactions No formal veterinary drug interaction studies exist for Yunnan Baiyao. The theoretical concerns follow from its proposed mechanisms. If the product does promote platelet activation or clot formation, combining it with drugs that inhibit platelets, such as clopidogrel, or with anticoagulants, such as heparin or warfarin, could produce unpredictable results in either direction. Combining it with other procoagulant therapies could in theory increase thrombotic risk, though this has not been demonstrated in animals. Because caowu contains aconite alkaloids, combining Yunnan Baiyao with other drugs that affect cardiac conduction or with other herbal products containing aconite would be a particular concern. Any pet receiving multiple supplements should have those supplements reviewed together by a veterinarian, since supplement interactions are rarely studied and often unrecognized. ## How It Compares With Alternatives For bleeding that requires a real pharmacological effect, veterinarians have options with far better evidence. Epsilon aminocaproic acid is an antifibrinolytic drug that slows the breakdown of clots, and it has been used in dogs with right atrial masses and pericardial effusion. A retrospective study compared dogs treated with Yunnan Baiyao alone, Yunnan Baiyao plus epsilon aminocaproic acid, and pericardiocentesis alone. There was no significant difference between groups in the number of pericardiocenteses performed, the time to recurrence of clinical signs, or median survival, and no side effects were attributed to either drug [18]. That study is small and retrospective, but it is one of the few direct comparisons available, and it did not show an advantage for Yunnan Baiyao. For hemangiosarcoma specifically, the treatments with the strongest evidence are surgery and chemotherapy, not herbal supplements. The retrospective study that found an association between Yunnan Baiyao and longer disease-free interval also found that blood transfusion and metastatic disease at surgery shortened it [5]. Those findings point to disease stage and conventional treatment as the dominant factors. For idiopathic renal hematuria, the two case reports in which Yunnan Baiyao failed both went on to successful sclerotherapy, a procedure in which a sclerosing solution is instilled into the renal pelvis to stop the bleeding [3][19]. That is a useful contrast: when a bleeding problem has an identifiable mechanical cause, a procedure directed at the cause may succeed where a systemic supplement does not. For nosebleeds, the alternatives depend on the cause. They include treating any underlying clotting disorder, controlling blood pressure, managing nasal disease, and in some cases using topical agents or cautery. Yunnan Baiyao is sometimes used alongside these measures rather than instead of them. ## Regulatory Status Yunnan Baiyao is not approved by the US Food and Drug Administration as a drug for any indication, in humans or in animals. It is sold as a dietary supplement. That distinction matters. Dietary supplements are not required to demonstrate efficacy before marketing, and manufacturers are not required to disclose the full composition of a proprietary blend on the label in the way a drug manufacturer must disclose active ingredients and amounts. For veterinary use, this means the product is being used off-label in essentially every situation. There is no FDA-approved veterinary formulation, no approved dose, and no approved indication. A veterinarian who recommends it is making a clinical judgment based on limited evidence, and a pet owner who buys it online is purchasing a product whose content may vary between batches and whose safety has not been established in dogs or cats by a regulatory agency. The Merck Veterinary Manual includes a video resource on Yunnan Baiyao, and VCA Animal Hospitals maintains a client-facing page on the product, which reflects that it is widely encountered in practice even without formal approval [20][21]. ## Clinical Relevance, Limitations and Common Mistakes The clinical relevance of Yunnan Baiyao in [veterinary medicine](/blog/careers/veterinary-medicine-careers-from-clinical-practice-to-public-health) is real in the sense that it is widely used, and the evidence base is thin in the sense that it does not support confident claims about efficacy. Those two facts coexist, and understanding both is what allows a veterinarian or owner to make a reasonable decision. The most common mistake is treating a positive outcome as proof of efficacy. A dog with a nosebleed that stops after starting Yunnan Baiyao may have stopped bleeding for many reasons, including natural resolution of the underlying cause. Without [a control group](/blog/guides/understanding-control-groups-in-clinical-trials-types-and-selection), that observation carries almost no weight. The veterinary literature contains several studies that were designed to answer the efficacy question properly, and most of them found no significant effect on clotting parameters in healthy animals [11][15][13]. The one positive canine study used a different dose and has not been replicated [12]. A second mistake is assuming that because the product is natural or traditional, it is safe. The formula contains Aconitum kusnezoffii, a plant with genuinely toxic alkaloids, and toxicology studies confirm that the formula has a measurable toxicological profile [1][17]. Natural does not mean harmless, and an undisclosed formula means the prescriber cannot know exactly what is being given. A third mistake is using Yunnan Baiyao instead of a treatment with better evidence. In dogs with hemangiosarcoma, the decisions that matter most are about surgery, staging, and chemotherapy. In dogs with unexplained bleeding, the decisions that matter most are about finding the cause. Using a supplement as a substitute for diagnosis or for proven treatment delays effective care. A fourth mistake is failing to record what was given. Because the product is a supplement with variable content, noting the brand, form, dose, and dates of use helps if a problem develops later. A fifth mistake is extrapolating from human trials. The human surgical literature includes a randomized trial showing reduced blood loss with preoperative Yunnan Baiyao [7], and reviews cite human benefits in wound healing and inflammation [2]. Those findings are relevant background, but species differences in drug absorption, metabolism, and clotting mean they cannot be assumed to apply to dogs or cats. Individual patients vary, and any decision about using Yunnan Baiyao in a specific animal should be made with a veterinarian who knows that animal's history, diagnosis, and other medications. ## Frequently Asked Questions ### What is Yunnan Baiyao used for in dogs? It is most often used to try to reduce bleeding in dogs with hemangiosarcoma, nosebleeds, or bleeding around surgery. It is also used topically on wounds. The evidence that it works for these uses in dogs is limited and inconsistent. ### Does Yunnan Baiyao actually stop bleeding in dogs? The controlled canine studies do not show a reliable effect on clotting tests. One study found a stronger clot at a 250 mg twice-daily dose, while two studies using 1000 mg every 12 hours found no clinically significant change [11][12][13]. ### Is Yunnan Baiyao FDA-approved for animals? No. It is not approved by the FDA as a drug for humans or animals and is sold as a dietary supplement. There is no approved veterinary dose or indication. ### What is inside Yunnan Baiyao? The full formula is proprietary and undisclosed. Panax notoginseng is a key known component, and Aconitum kusnezoffii (caowu) is also present [1]. ### Can cats take Yunnan Baiyao? Cats have been given it in a study, but vomiting was common, with one cat withdrawn for severe vomiting, and treated cats had a significant decrease in hematocrit and red blood cell count [14]. Cats appear to tolerate it less well than dogs. ### What are the side effects of Yunnan Baiyao in pets? Gastrointestinal upset is the most reported effect, including mild diarrhea in dogs and vomiting in cats. The formula also contains aconite alkaloids, which are toxic, so any neurological or cardiac signs after dosing warrant stopping the product and calling a veterinarian [1][14]. ### Does Yunnan Baiyao help dogs with hemangiosarcoma live longer? The evidence is not strong enough to say. One retrospective study found an association between recorded Yunnan Baiyao use and longer disease-free interval, and one case report described a two-year survival on a combined regimen [5][6]. Neither can prove the drug caused the outcome. ### Should I give Yunnan Baiyao before my dog's surgery? That decision belongs to the attending veterinarian. There is no canine evidence that it reduces surgical blood loss, and its effect on clotting tests in dogs is inconsistent [11][12][13]. ## Related Articles - [Antimicrobial Stewardship in Equine Respiratory Disease: Evidence-Based Use](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-equine-respiratory-disease-evidence-based) - [Qualitative Data Examples: How to Recognize and Use Non-Numerical Evidence](/blog/guides/qualitative-data-examples-how-to-recognize-and-use-non-numerical-evidence) - [Anesthesia Machine Safety Checks for Laboratory Animal Use](/knowledge/veterinary-medicine/laboratory-animal-science/anesthesia-machine-safety-checks-laboratory-animal-use) - [Prednisone for Dogs: Uses, Side Effects, and Safety Guidelines](/knowledge/veterinary-medicine/preventive-care/prednisone-for-dogs-uses-side-effects-and-safety-guidelines) - [Can Epigenetics Be Reversed? Mechanisms and Evidence](/knowledge/molecular-biology/epigenetics-be-reversed) - [Semiconservative Replication: Mechanism and Evidence](/knowledge/molecular-biology/semiconservative-replication) - [Pepcid for Dogs: Dosage, Uses, and Safety Guide](/knowledge/veterinary-medicine/pet-medication-guide/pepcid-for-dogs-dosage-uses-and-safety-guide) - [Clonidine for Dogs: Uses, Dosing, and Safety](/knowledge/veterinary-medicine/pet-medication-guide/clonidine-for-dogs-uses-dosing-and-safety) - [Amantadine for Dogs: Uses, Doses, and Safety](/knowledge/veterinary-medicine/clinical-pharmacology/amantadine-for-dogs-uses-doses-and-safety) ## Sources 1. [Research Advances in Pharmacology, Safety, and Clinical Applications of Yunnan Baiyao, a Traditional Chinese Medicine Formula.](https://pubmed.ncbi.nlm.nih.gov/34899330/) 2. [Yunnan Baiyao (YNBY): pharmacological mechanisms, therapeutic applications, and clinical evidence.](https://pubmed.ncbi.nlm.nih.gov/40703359/) 3. [Endoscopy-guided, renal-sparing sclerotherapy in 2 dogs with idiopathic renal hematuria.](https://pubmed.ncbi.nlm.nih.gov/40513608/) 4. [In vitro effects of Yunnan Baiyao on canine hemangiosarcoma cell lines.](https://pubmed.ncbi.nlm.nih.gov/24976212/) 5. [Long-term postoperative effects of administration of allogeneic blood products in 104 dogs with hemangiosarcoma.](https://pubmed.ncbi.nlm.nih.gov/30242852/) 6. [Hemangiosarcoma in a Dog: Unusual Presentation and Increased Survival Using a Complementary/Holistic Approach Combined with Metronomic Chemotherapy.](https://pubmed.ncbi.nlm.nih.gov/29955437/) 7. [Effects of the preoperative administration of Yunnan Baiyao capsules on intraoperative blood loss in bimaxillary orthognathic surgery: a prospective, randomized, double-blind, placebo-controlled study.](https://pubmed.ncbi.nlm.nih.gov/19153029/) 8. [Yunnan Baiyao-loaded multifunctional microneedle patches for rapid hemostasis and cutaneous wound healing.](https://pubmed.ncbi.nlm.nih.gov/37280566/) 9. [[Histological study on repairing experimental pulp chamber floor perforations with yunnan bai-yao in dog].](https://pubmed.ncbi.nlm.nih.gov/8000227/) 10. [Yunnan Baiyao diminishes lipopolysaccharide-induced inflammation in osteoclasts.](https://pubmed.ncbi.nlm.nih.gov/32189353/) 11. [The effects of oral administration of Yunnan Baiyao on blood coagulation in beagle dogs as measured by kaolin-activated thromboelastography and buccal mucosal bleeding times.](https://pubmed.ncbi.nlm.nih.gov/28154462/) 12. [A prospective evaluation of oral Yunnan Baiyao therapy on thromboleastographic parameters in apparently healthy dogs.](https://pubmed.ncbi.nlm.nih.gov/29727528/) 13. [Effects of Yunnan Baiyao on blood coagulation parameters in beagles measured using kaolin activated thromboelastography and more traditional methods.](https://pubmed.ncbi.nlm.nih.gov/30255049/) 14. [A prospective evaluation of oral Yunnan Baiyao therapy on thromboelastographic parameters in apparently healthy cats.](https://pubmed.ncbi.nlm.nih.gov/31625678/) 15. [Randomized placebo-controlled study of the effects of Yunnan Baiyao on hemostasis in horses.](https://pubmed.ncbi.nlm.nih.gov/28738008/) 16. [The efficacy of Yunnan Baiyao on haemostasis and antiulcer: a systematic review and meta-analysis of randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/24753739/) 17. [Network pharmacology combined with metabolomics approach to investigate the protective role and detoxification mechanism of Yunnan Baiyao formulation.](https://pubmed.ncbi.nlm.nih.gov/32629383/) 18. [Use of Yunnan Baiyao and epsilon aminocaproic acid in dogs with right atrial masses and pericardial effusion.](https://pubmed.ncbi.nlm.nih.gov/27669112/) 19. [[Bilateral renal sclerotherapy as a treatment option in a mixed breed male dog with idiopathic renal haematuria].](https://pubmed.ncbi.nlm.nih.gov/26109212/) 20. [Video: Yunnan Baiyao-Merck Veterinary Manual](https://www.merckvetmanual.com/multimedia/video/yunnan-baiyao) 21. [Yunnan Baiyao - VCA Animal Hospitals](https://vcahospitals.com/know-your-pet/yunnan-baiyao)